Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

Core Insights - Revolution Medicines, Inc. has received a non-transferrable voucher from the FDA for daraxonrasib (RMC-6236) under the Commissioner's National Priority Voucher pilot program, recognizing the unmet need for treatments for RAS-addicted cancers [1][3] - Daraxonrasib is currently being evaluated in two global Phase 3 clinical trials targeting metastatic pancreatic ductal adenocarcinoma and metastatic non-small cell lung cancer [2][5] - The company anticipates data readout from the RASolute 302 trial in 2026 and is committed to working with the FDA to expedite the drug's availability to patients [3][4] Company Overview - Revolution Medicines is focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes multiple RAS(ON) inhibitors [6] - The company's RAS(ON) inhibitors include daraxonrasib (multi-selective), elironrasib (G12C-selective), and zoldonrasib (G12D-selective), with plans for RMC-5127 (G12V-selective) to enter clinical development soon [6] - The company aims to address a wide range of cancers driven by oncogenic RAS mutations, including pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer [5][6]